MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
common stock and...
$485,000
Net cash provided by
financing activities
$397,502
Canceled cashflow
$87,498
Increase (decrease) in
cash and equivalents
-$160,771
Canceled cashflow
$397,502
Stock-based compensation
$177,867
Other accrued
liabilities
$142,074
Accounts payable
$47,481
Depreciation and
amortization
$1,157
Foreign currency
adjustment
-$539
Repayment of notes payable
to related parties
$87,498
Net cash used in
operating activities
-$519,355
Canceled cashflow
$369,118
Net cash used in
investing activities
-$38,918
Net loss
-$814,012
Accrued compensation
-$54,593
Prepaid expenses
-$16,520
Amortization of rou assets,
net of liabilities
-$3,348
Capitalized software
development
$38,472
Purchase of furniture and
computer equipment
$446
Back
Back
Cash Flow
source: myfinsight.com
REGENEREX PHARMA, INC. (RGPX)
REGENEREX PHARMA, INC. (RGPX)